Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy
Open Access
- 7 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4), e0152840
- https://doi.org/10.1371/journal.pone.0152840
Abstract
SMT C1100 is a utrophin modulator being evaluated as a treatment for Duchenne muscular dystrophy (DMD). This study, the first in pediatric DMD patients, reports the safety, tolerability and PK parameters of single and multiple doses of SMT C1100, as well as analyze potential biomarkers of muscle damage. This multicenter, Phase 1 study enrolled 12 patients, divided equally into three groups (A–C). Group A were given 50 mg/kg on Days 1 and 11, and 50 mg/kg bid on Days 2 to 10. Group B and C received 100 mg/kg on Days 1 and 11; Group B and Group C were given 100 mg/kg bid and 100 mg/kg tid, respectively, on Days 2 to 10. A safety review was performed on all patients following the single dose and there was at least 2 weeks between each dose escalation, for safety and PK review. Adverse events (AEs) were monitored throughout the study. Most patients experienced mild AEs and there were no serious AEs. Two patients required analgesia for pain (headache, ear pain and toothache). One patient experienced moderate psychiatric AEs (abnormal behaviour and mood swings). Plasma concentrations of SMT C1100 at Days 1 and 11 indicated a high degree of patient variability regardless of dose. Unexpectedly the SMT C1100 levels were significantly lower than similar doses administered to healthy volunteers in an earlier clinical study. In general, individual baseline changes of creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase levels fell with SMT C1100 dosing. SMT C1100 was well tolerated in pediatric DMD patients. ClinicalTrials.gov NCT02383511Keywords
This publication has 14 references indexed in Scilit:
- Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteersThe Journal of Clinical Pharmacology, 2015
- Intellectual Ability in the Duchenne Muscular Dystrophy and Dystrophin Gene Mutation LocationBalkan Journal of Medical Genetics, 2014
- Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx MousePLOS ONE, 2011
- Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular DystrophyJournal of Medicinal Chemistry, 2011
- Advances in Duchenne muscular dystrophy gene therapyNature Reviews Genetics, 2003
- Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signalingProceedings of the National Academy of Sciences of the United States of America, 2003
- Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression systemHuman Molecular Genetics, 2002
- Expression of full-length utrophin prevents muscular dystrophy in mdx miceNature Medicine, 1998
- Molecular and Functional Analysis of the Utrophin PromoterNucleic Acids Research, 1996
- Population frequencies of inherited neuromuscular diseases—A world surveyNeuromuscular Disorders, 1991